<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drugs that should be avoided or used with caution in patients with heart failure</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drugs that should be avoided or used with caution in patients with heart failure</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drugs that should be avoided or used with caution in patients with heart failure</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen S Gottlieb, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A number of medications that are in common clinical use are relatively or absolutely contraindicated in patients with heart failure (HF), either because they can cause exacerbations of HF or because there is a higher risk of adverse reactions in such patients  (<a class="graphic graphic_table graphicRef68838" href="/z/d/graphic/68838.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Drug-induced exacerbation or decompensation of established HF is a relatively common occurrence. Its prevention requires frequent reassessment and meticulous management of often complex medication regimens.</p><p>Utilization of drugs that can exacerbate HF is common in patients with HF. In a study from Denmark, 34 percent of patients received at least one nonsteroid anti-inflammatory agent or cyclooxygenase-2 inhibitor after discharge for first hospitalization for HF [<a href="#rid2">2</a>]. Use of some of these drugs may be increasing. As an example, a review of Medicare beneficiaries hospitalized with the diagnoses of HF and diabetes mellitus found that the proportion using <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> and/or a thiazolidinedione increased from 13.5 percent in 1998 to 1999 to 24.4 percent in 2000 to 2001 [<a href="#rid3">3</a>].</p><p>Management of patients with HF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>General principles for avoiding drug-induced worsening of HF include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Recognition of the basic mechanisms by which drugs can exacerbate HF including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sodium retention</p><p class="bulletIndent2"><span class="glyph">•</span>Negative inotropic effect</p><p class="bulletIndent2"><span class="glyph">•</span>Direct cardiotoxicity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identification of significant drug interactions among medications used to treat HF and concomitant diseases. A complete and updated list of medications including prescription or nonprescription vitamins, supplements, and remedies should be obtained at each encounter. Common HF drugs often affected by pharmacokinetic drug interactions include: <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and beta-blockers (via CYP 2D6 metabolism).</p><p></p><p class="bulletIndent1">Examples of significant pharmacodynamic interactions that may occur in patients with HF include: combinations of drugs increasing the risk of hyperkalemia (eg, angiotensin converting enzyme inhibitor plus potassium supplement), <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> with hypokalemia increasing the risk of digoxin-induced arrhythmias, QTc-prolonging drugs and electrolyte disturbances increasing the risk of torsades de pointes, and the combination of drugs prescribed for HF (eg, angiotensin converting enzyme inhibitor and beta blocker) with other drugs with blood pressure-lowering effects (eg, alpha-1-blockers) increasing the risk of hypotension. (See <a class="local">'Drugs that may cause hyperkalemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Awareness that drug absorption, distribution, and clearance can be significantly altered during acute overload state which may cause gut edema, hepatic congestion, and/or renal insufficiency.</p><p></p><p class="bulletIndent1">For example, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> dose requirement is generally much lower in an acute exacerbation versus chronic stable HF. <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> clearance may decrease, and a trough should be checked during acute HF exacerbation to monitor for risk of toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surveillance for drug effects that are altered as chronic HF progresses. For example, the volume of distribution tends to decrease for certain HF drugs (eg, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>) as HF advances as well as with aging or renal failure. Lower load and maintenance dosing may be required to avoid an increase in risk of drug toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring HF management involving frequent assessment and adjustment of several drugs with similar pharmacodynamic effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should receive education about the drugs they are prescribed. They should also receive information about drugs that should be avoided including nonprescription medications, alternative treatments, and dietary supplements.</p><p></p><p>Consultation with a clinical pharmacist with cardiovascular expertise may be valuable in some instances.</p><p class="headingAnchor" id="H3"><span class="h1">DRUGS</span><span class="headingEndMark"> — </span>Some drugs and classes of drugs that may cause or exacerbate HF are discussed here. A 2016 American Heart Association Scientific Statement on drugs that may cause or exacerbate HF provides an extensive tabulation of drugs of concern [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Nonsteroidal anti-inflammatory drugs</span><span class="headingEndMark"> — </span>Nonsteroidal anti-inflammatory drug (NSAID) use (nonselective or cyclooxygenase [COX]-2 selective [coxibs]) is associated with increased risk of first occurrence or exacerbation of HF. NSAID use is also associated with increased risk of renal dysfunction and hyperkalemia and impairment of responses to angiotensin converting enzyme (ACE) inhibitors and diuretics. Observational data in patients with HF indicated an association between NSAID (nonselective or coxibs) use and increased mortality. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects", section on 'NSAIDs and heart failure'</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Aspirin</span><span class="headingEndMark"> — </span>While patients with HF and vascular disease (including coronary disease) and/or cardiovascular risk factors may have indications for <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> use, the risks and benefits of aspirin in patients with HF but without other indications are not well established. Aspirin use in patients with HF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3502.html" rel="external">"Antithrombotic therapy in patients with heart failure"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Calcium channel blockers</span><span class="headingEndMark"> — </span>Some initial studies suggested a possible deleterious effect of calcium channel blockers in patients with HF with reduced ejection fraction (HFrEF), while later trials with the vasoselective calcium channel blocker <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> showed a neutral effect on morbidity and mortality [<a href="#rid5">5,6</a>]. Thus, although there is <strong>NO</strong> direct role for calcium channel blockers in the management of HFrEF, amlodipine appears to be safe in patients with HF and can be used if treatment with a calcium channel blocker is necessary for another indication, such as angina or hypertension. (See  <a class="medical medical_review" href="/z/d/html/3455.html" rel="external">"Calcium channel blockers in heart failure with reduced ejection fraction"</a>.)</p><p class="headingAnchor" id="H39799436"><span class="h2">Drugs that may cause hyperkalemia</span><span class="headingEndMark"> — </span>Patients with HFrEF are treated with drugs that raise serum potassium levels (eg, inhibitors of the renin-angiotensin-aldosterone system such as ACE inhibitor, angiotensin II receptor blocker [ARB], or sacubitril/<a class="drug drug_general" data-topicid="10036" href="/z/d/drug information/10036.html" rel="external">valsartan</a> and mineralocorticoid receptor antagonist [MRA]). Monitoring of serum potassium levels is recommended for patients taking one or more of these inhibitors of the renin-angiotensin-aldosterone system, and additional monitoring is recommended after an MRA is added to an ACE inhibitor or an ARB. Routine use of the combination of an ACE inhibitor and an ARB is potentially harmful and should be avoided. Likewise, sacubitril/valsartan should never be taken with an ACE inhibitor. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction"</a>.)</p><p>For patients taking an ACE inhibitor or ARB and/or MRA, potassium supplements should be used only as needed (eg, if required to offset potassium wasting caused by loop diuretic therapy), and potassium sparing diuretics such as <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a> and <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a> should generally be avoided.</p><p class="headingAnchor" id="H575631452"><span class="h2">Trimethoprim-sulfamethoxazole</span><span class="headingEndMark"> — </span>In patients taking an ACE inhibitor, ARB, or MRA, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) should be avoided or used with caution with careful monitoring. An elevated risk of hyperkalemia and acute kidney injury has been observed in patients treated with ACE inhibitor plus TMP-SMX [<a href="#rid7">7</a>], and an elevated risk of hyperkalemia has been observed in patients treated with MRA plus TMP-SMX [<a href="#rid8">8,9</a>]. In addition, an increased risk of sudden death has been observed in patients treated with ACE inhibitor or ARB plus TMP-SMX [<a href="#rid10">10</a>] or <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> plus TMP-SMX [<a href="#rid11">11</a>], although a causal relationship has not been established.</p><p class="headingAnchor" id="H8"><span class="h2">Antidepressants</span><span class="headingEndMark"> — </span>Depression is common in patients with HF and is associated with worse outcomes, including increased mortality rates. While concern has been raised that certain antidepressants, particularly tricyclic antidepressants (TCAs), may cause adverse cardiovascular effects, an analysis found that depression rather than antidepressant use was independently associated with worse outcomes. (See  <a class="medical medical_review" href="/z/d/html/3477.html" rel="external">"Predictors of survival in heart failure with reduced ejection fraction"</a>.)</p><p>Limited data are available on the safety and efficacy of antidepressants in patients with HF. A review of randomized controlled trials found that TCAs and selective serotonin reuptake inhibitors were associated with similar rates of major adverse cardiovascular events (such as HF, myocardial infarction, stroke, or cardiovascular death) [<a href="#rid12">12</a>]. However, other cardiovascular side effects (particularly palpitations) were more common among patients taking TCAs.</p><p class="headingAnchor" id="H9"><span class="h2">Oral hypoglycemic agents</span><span class="headingEndMark"> — </span>The oral hypoglycemic agents thiazolidinediones and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> pose particular risks in patients with HF.</p><p class="headingAnchor" id="H10"><span class="h3">Thiazolidinediones</span><span class="headingEndMark"> — </span>Thiazolidinediones cause fluid retention, which may precipitate HF. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">"Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Metformin</span><span class="headingEndMark"> — </span>Patients with HF who take <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> are at increased risk of potentially lethal lactic acidosis as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Lactic acidosis'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Phosphodiesterase inhibitors</span><span class="headingEndMark"> — </span>Concerns have been raised about the safety of phosphodiesterase-3 (PDE-3), and phosphodiesterase-5 (PDE-5) inhibitors in patients with HF. <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">Cilostazol</a> and <a class="drug drug_general" data-topicid="8593" href="/z/d/drug information/8593.html" rel="external">anagrelide</a> should be avoided in patients with HF.</p><p class="headingAnchor" id="H13"><span class="h3">PDE-3 inhibitors</span><span class="headingEndMark"> — </span>In patients with HFrEF, the chronic use of oral PDE-3 inhibitors for inotropic therapy was associated with <strong>increased mortality</strong> compared with placebo [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction", section on 'Intravenous phosphodiesterase-3 inhibitors'</a>.)</p><p><a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">Cilostazol</a> is a PDE-3 inhibitor approved by the United States Food and Drug Administration (FDA) for the treatment of intermittent claudication. While it is not established that cilostazol impacts mortality in patients with HF, the FDA regards HF of any severity as a contraindication to the use of cilostazol [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction", section on 'Intravenous phosphodiesterase-3 inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/8210.html" rel="external">"Management of claudication due to peripheral artery disease", section on 'Cilostazol'</a>.)</p><p><a class="drug drug_general" data-topicid="8593" href="/z/d/drug information/8593.html" rel="external">Anagrelide</a> is a PDE-3 inhibitor used in the treatment of proliferative hematologic disorders such as essential thrombocythemia and polycythemia vera. (See  <a class="medical medical_review" href="/z/d/html/4486.html" rel="external">"Essential thrombocythemia: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4534.html" rel="external">"Polycythemia vera and secondary polycythemia: Treatment and prognosis"</a>.)</p><p><a class="drug drug_general" data-topicid="8593" href="/z/d/drug information/8593.html" rel="external">Anagrelide</a> has positive inotropic and vasodilatory effects. The development of fluid retention, and less commonly HF with or without development of cardiomyopathy, has been reported with its use, although controlled data are lacking. It may also cause high-output HF. Anagrelide use should be avoided in patients with HF. (See  <a class="medical medical_review" href="/z/d/html/4486.html" rel="external">"Essential thrombocythemia: Treatment and prognosis", section on 'Anagrelide'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">PDE-5 inhibitors</span><span class="headingEndMark"> — </span>PDE-5 inhibitors, such as <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="10172" href="/z/d/drug information/10172.html" rel="external">vardenafil</a>, and <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>, are widely used in the treatment of erectile dysfunction in men. These drugs are vasodilators that can lower pulmonary and systemic arterial pressure.</p><p>The use of PDE-5 inhibitors with any form of nitrate therapy (regular or intermittent) is contraindicated. <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">Nitroglycerin</a> is contraindicated after the use of <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> within the previous 24 hours or <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> within 48 hours and may have an augmented hypotensive effect beyond these time windows. An American College of Cardiology/American Heart Association expert consensus document concluded that the PDE-5 inhibitors are potentially hazardous in patients with HF who have borderline low blood pressure and/or low volume status. (See  <a class="medical medical_review" href="/z/d/html/1541.html" rel="external">"Sexual activity in patients with cardiovascular disease"</a>.)</p><p>Clinical data on use of these agents in patients with HF are limited. In a randomized comparison of <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> to placebo in 35 patients with New York Heart Association class II to III HF who were not taking nitrates, a single 50 mg dose of sildenafil caused an asymptomatic 6 mmHg decrease in mean systemic blood pressure at two hours that had resolved by four hours [<a href="#rid15">15</a>]. Over a six-week course of therapy, no patient developed symptoms of hypotension or worsening of HF while taking sildenafil. In another trial of 34 HF patients randomly assigned to receive either sildenafil or placebo, no significant difference in incidence of symptomatic hypotension was observed [<a href="#rid16">16</a>].</p><p>The potential role of <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> in selected patients with HF complicated by pulmonary hypertension is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3478.html" rel="external">"Investigational therapies for management of heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Targeted therapy for pulmonary hypertension'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Antiarrhythmic agents</span><span class="headingEndMark"> — </span>Most antiarrhythmic drugs have some negative inotropic activity and, in patients with reduced left ventricular function, can precipitate HF [<a href="#rid1">1</a>]. The further reduction in left ventricular function can also impair the elimination of these drugs, resulting in drug toxicity. In addition, some antiarrhythmic drugs exert a possible proarrhythmic effect, particularly class I agents and the class III agents <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> and <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>. HF is a risk factor for torsades de pointes in patients receiving the class III agents ibutilide, sotalol, and <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>.</p><p><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> is generally considered to be less proarrhythmic than other antiarrhythmic agents and is generally the preferred drug for treatment of arrhythmias in HF. Amiodarone side effects and drugs interactions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF", section on 'Antiarrhythmic drugs'</a> and  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Chemotherapy agents</span><span class="headingEndMark"> — </span>Cardiotoxic chemotherapeutic agents should be avoided in patients with HF. Cardiotoxic agents include anthracyclines, high-dose <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a>, and <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>. (See  <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"</a> and  <a class="medical medical_review" href="/z/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Androgens</span><span class="headingEndMark"> — </span>Limited data are available on the impact of androgen therapy on cardiovascular function. Although disorders including sudden death, hypertension, and left ventricular hypertrophy have been reported in individuals taking androgens, a causal relationship has not been established. FDA-approved labeling for the testosterone patch includes a warning that edema, with or without HF, may be a complication of androgen treatment in patients with pre-existing cardiac, renal, or hepatic disease [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/7475.html" rel="external">"Use of androgens and other hormones by athletes"</a>.)</p><p>The 2010 Endocrine Society guidelines on testosterone therapy for men with androgen deficiency recommended against testosterone therapy in patients with uncontrolled or poorly controlled HF [<a href="#rid18">18</a>].</p><p>In men with HF, deficiency in anabolic hormones, including androgens (testosterone, dehydroepiandrosterone), is common and is an independent marker of poor prognosis. However, the nature of the relationship between androgen deficiency and HF severity is not known. Available data are insufficient to recommend androgen therapy in patients with HF. (See  <a class="medical medical_review" href="/z/d/html/3477.html" rel="external">"Predictors of survival in heart failure with reduced ejection fraction"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Sodium-containing preparations</span><span class="headingEndMark"> — </span>Some drug preparations contain clinically significant quantities of sodium. For example, <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> and Fleet PhosPho soda include one and two grams of sodium, respectively, per dose. An additional concern with <a class="drug drug_general" data-topicid="10269" href="/z/d/drug information/10269.html" rel="external">sodium phosphate</a> preparations is that ACE inhibitors (used to treat HFrEF) may enhance the risk of acute phosphate nephropathy [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Antihistamines</span><span class="headingEndMark"> — </span>Long QT syndrome has been reported with some second generation antihistamines (terfenadine and astemizole) but not others (eg, <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">fexofenadine</a>, <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a>).</p><p class="headingAnchor" id="H22"><span class="h2">Theophylline</span><span class="headingEndMark"> — </span>There is a narrow therapeutic index for methylxanthines such as <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> in treating chronic airway disease. During acute decompensation of HF, theophylline serum levels may increase, causing toxicity. Tachycardia and atrial arrhythmias may occur at serum concentrations considered therapeutic, particularly among patients with heart disease. If this drug cannot be avoided in HF, dose reduction with monitoring of levels or discontinuation of medication may be required. (See  <a class="medical medical_review" href="/z/d/html/560.html" rel="external">"Theophylline use in asthma"</a> and  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Theophylline, monitored by drug levels'</a>.)</p><p class="headingAnchor" id="H2944173753"><span class="h2">TNF-alpha inhibitors</span><span class="headingEndMark"> — </span>Tumor necrosis factor-alpha inhibitors may be associated with new onset or worsening of pre-existing HF. United States product information includes HF as a warning for these agents as a class and a specific contraindication for <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> dosed over 5 mg/kg. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Heart failure'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">"Natural" remedies and supplements</span><span class="headingEndMark"> — </span>Naturoceutical products or dietary supplements may be construed by some patients as benign, although they are not of proven benefit and some may pose health risks. For example, ephedra (also called Ma huang) is a plant source of <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">ephedrine</a> that is contained in some products promoted for athletic performance enhancement or weight loss. Case reports suggest that ephedra may cause HF and left ventricular systolic dysfunction [<a href="#rid20">20</a>]. The FDA has banned dietary supplements containing ephedra since 2004.</p><p class="headingAnchor" id="H2688857251"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a>.)</p><p class="headingAnchor" id="H8052714"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>A number of medications that are in common clinical use are relatively or absolutely contraindicated in patients with heart failure (HF), either because they can cause exacerbations of HF or because there is a higher risk of adverse reactions in such patients  (<a class="graphic graphic_table graphicRef68838" href="/z/d/graphic/68838.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>General principles for avoiding drug-induced exacerbation of HF include recognition of the basic mechanisms by which drugs can exacerbate HF, identification of significant drug interactions, awareness of potential alterations in pharmacokinetics in the setting of HF, surveillance for changes in drug effects with changes in HF status, and monitoring the pharmacodynamic effects of HF management. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroid anti-inflammatory agent use in HF patients is associated with increased risk of HF exacerbation, increased renal dysfunction, and impairment of responses to angiotensin converting enzyme inhibitors and diuretics. (See <a class="local">'Nonsteroidal anti-inflammatory drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The oral hypoglycemic agents thiazolidinediones and <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> pose particular risks in patients with HF. Thiazolidinediones cause fluid retention and may precipitate HF. Patients with HF who take metformin are at increased risk of potentially lethal lactic acidosis. (See <a class="local">'Oral hypoglycemic agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerns have been raised about the safety of phosphodiesterase-3 (PDE-3) inhibitors in patients with HF. PDE-5 inhibitors may be used in carefully-selected patients with HF, but are potentially hazardous in patients with low blood pressure and/or volume depletion, and are contraindicated in any patient taking nitrate therapy. (See <a class="local">'Phosphodiesterase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most antiarrhythmic agents have some negative inotropic activity and some have proarrhythmic effects. <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> is generally considered less proarrhythmic than other antiarrhythmic agents and is generally the preferred drug for treatment of arrhythmias in HF. (See <a class="local">'Antiarrhythmic agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug list review should include any naturoceutical products or dietary supplements. Although these may be construed by some patients as benign, some may pose health risks. (See <a class="local">'"Natural" remedies and supplements'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004; 164:709.</a></li><li><a class="nounderline abstract_t">Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169:141.</a></li><li><a class="nounderline abstract_t">Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003; 290:81.</a></li><li><a class="nounderline abstract_t">Pagell RL, O'Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016; 134:e32.</a></li><li><a class="nounderline abstract_t">WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.</a></li><li class="breakAll">http://circ.ahajournals.org/content/suppl/2013/06/04/CIR.0b013e31829e8776.DC1/Online_Data_Supplement.pdf.</li><li><a class="nounderline abstract_t">Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother 2013; 47:1618.</a></li><li><a class="nounderline abstract_t">Michel A, Martín-Pérez M, Ruigómez A, García Rodríguez LA. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail 2015; 17:205.</a></li><li><a class="nounderline abstract_t">Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ 2011; 343:d5228.</a></li><li><a class="nounderline abstract_t">Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014; 349:g6196.</a></li><li><a class="nounderline abstract_t">Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ 2015; 187:E138.</a></li><li><a class="nounderline abstract_t">Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry 2006; 51:923.</a></li><li><a class="nounderline abstract_t">Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468.</a></li><li class="breakAll">www.fda.gov/cder/news/cilostazol/default.htm (Accessed on February 18, 2004).</li><li><a class="nounderline abstract_t">Webster LJ, Michelakis ED, Davis T, Archer SL. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med 2004; 164:514.</a></li><li><a class="nounderline abstract_t">Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555.</a></li><li class="breakAll">http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac40e05b-6e67-4ff9-a0e8-2e897e71b282 (Accessed on September 30, 2014).</li><li><a class="nounderline abstract_t">Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1715.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005; 16:3389.</a></li><li><a class="nounderline abstract_t">Peters CM, O'Neill JO, Young JB, Bott-Silverman C. Is there an association between ephedra and heart failure? a case series. J Card Fail 2005; 11:9.</a></li></ol></div><div id="topicVersionRevision">Topic 3499 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15078640" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Keeping your patient with heart failure safe: a review of potentially dangerous medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171810" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12837715" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Metformin and thiazolidinedione use in Medicare patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27400984" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741058" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741058" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24259630" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25581138" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911446" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359996" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25646289" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17249635" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944425" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944425" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006828" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785618" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785618" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562364" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16192415" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15704057" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is there an association between ephedra and heart failure? a case series.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
